Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 29 publications
Prostate-Specific Membrane Antigen Radioligand Therapy in Patients with Aggressive-Variant Prostate Cancer.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: September 21, 2025
Multivariate Framework of Metabolism in Advanced Prostate Cancer Using Whole Abdominal and Pelvic Hyperpolarized 13C MRI-A Correlative Study with Clinical Outcomes.
Journal: Cancers
Published: April 02, 2025
Pre- or post-chemotherapy: effect on PSMA uptake.
Journal: EJNMMI research
Published: January 23, 2025
Early changes of PSMA PET expression after initiation of androgen receptor signaling inhibitors in CRPC: an international multicenter retrospective study.
Journal: European journal of nuclear medicine and molecular imaging
Published: December 09, 2024
Patients Can Administer Mobile Audio Recordings to Increase Knowledge in Advanced Prostate Cancer.
Journal: Cancer medicine
Published: August 16, 2024
Real-World Experience with 177Lu-PSMA-617 Radioligand Therapy After Food and Drug Administration Approval.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: October 19, 2023
Initial Experience with 68Ga-FAP-2286 PET Imaging in Patients with Urothelial Cancer.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: August 24, 2023
Single-dose 177Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 trial.
Journal: The Lancet. Oncology
Published: June 26, 2023
Diagnosis and management of neuroendocrine prostate cancer.
Journal: The Prostate
Published: June 14, 2023
Impact of Squamous Histology on Clinical Outcomes and Molecular Profiling in Metastatic Urothelial Carcinoma Patients Treated With Immune Checkpoint Inhibitors or Enfortumab Vedotin.
Journal: Clinical genitourinary cancer
Published: March 18, 2023
Somatic alterations of TP53 and MDM2 associated with response to enfortumab vedotin in patients with advanced urothelial cancer.
Journal: Frontiers in oncology
Published: February 08, 2023
Last Updated: 09/26/2026